The U.S. Food and Drug Administration (FDA) has recently approved expanded use of Amgen’s innovative product, marketed as Uplizna. This groundbreaking decision marks a significant milestone in the treatment of rare immune disorders. Also known as inebilizumab, Uplizna is the first FDA-approved therapy specifically targeting conditions associated with immunoglobulin G4 (IgG4-RD). This rare disorder, characterized by an overactive immune system that causes persistent inflammation and tissue scarring in vital organs such as the pancreas, liver, and kidneys, affects approximately 20,000 people across the United States.